
price data provid thomson reuter
number may add due round
reiter outperform rate share beat larg
anticip follow pre-announc focu today center
larg guidanc implic come year part
understand need cautiou ultomiri convers progress howev
amidst rapidli convert ex-u market soliri gmg launch continu
show q/q patient growth expect phase data once-weekli
ultomiri sc devic continu see good competit posit
nice way close report total revenu
beat coincid non-gaap ep beat
pre-announc earn landmark investor alreadi
anticip solid execut quarter soliri growth y/i
benefit gmg launch somewhat off-set russian biosimilar
competit longer anticip sell russian market
convers effort progress nice track hit target perhap
notabl result soliris/ultomiri convers metric
stand us german region respect japan
ultomiri launch pnh month ago approxim
market alreadi convert soliri ultomiri recal manag
guid achiev convers bottom line remain
impress progress thu far look similar dynam play
ahu space ultomiri launch begin
total revenu rang fall behind pre-
forthcom ultomiri ahu commerci launch lower effect
price vs pnh well convert pnh cohort fewer inject
enter mainten mode acknowledg meaning
headwind contend think base uptak gmg
market patient enthusiasm longer-dur product like ultomiri see
kol note overcom minor adjust estim
howev note increas size address pnh ahu
market model soliris/ultomiri revenu increas
vs slightli ahead guid rang
look ahead continu like competit posit although
guidanc leav us look understand need
conserv work launch dynam howev said
think hold strong competit posit complement
neurolog space lower metabol franchis revenu
tie guidanc await potenti data once-weekli ultomiri
subcutan format minor adjust estim
roll forward valuat year target remain unchang
outperform rate
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
larg anticip competit posit solid
wedbush view reiter outperform rate share beat
larg anticip follow pre-announc focu today center larg
guidanc implic come year part understand need
cautiou ultomiri convers progress howev amidst rapidli convert ex-u
market soliri gmg launch continu show q/q patient growth expect phase
data once-weekli ultomiri sc devic continu see good competit
takeaway report total revenu beat consensu
ws likewis non-gaap ep also beat consensu compani
previous announc total revenu y/i growth exceed beat larg
anticip see preview note figur illustr actual result
quarter compar ws consensu estim
overal complement franchis soliris/ultomiri remain strong foot manag
note convers pnh patient across differ region remain track figur
illustr trajectori perhap notabl us pnh market seen
roughli convers thu far give us confid compani
abil hit target convers elsewher convers among japanes
patient taken steeper step forward see figur manag continu
anticip ultomiri ahu launch proceed similar fashion
guidanc caus concern yet figur
summar chang manag guidanc total revenu guidanc
midpoint pre-exist consensu
appear somewhat impact weaker metabol franchis guid note
metabol franchis revenu guidanc midpoint roughli
pre-exist consensu
manag also note ultomiri ahu launch dynam consid
specif impact ahu price differenti versu pnh impact fewer
inject pnh mainten phase like benefit patient
load dose regimen patient remain therapi fewer infus
cours year
pipelin updat overal pipelin effort remain continu remain track numer
late-stag clinic develop program on-going see figur near-term
ultomiri phase readout anticip once-weekli on-bodi subcutan inject
think import life cycle-manag tool would look
profil similar ultomiri term efficaci along favor toler
model updat make sever chang current estim go forward
increas soliris/ultomiri revenu estim increas
estim address market opportun pnh ahu separ lower
strensiq revenu estim off-set increas kanuma revenu overal
metabol franchis revenu estim in-lin guid rang
increas expens assumpt roughli tie
guidanc final increas effect tax rate repres
increas figur summari chang
start new fiscal year roll forward valuat year
stay consist valuat methodolog appli net model chang
price target remain unchang deriv target appli
multipl non-gaap ep discount back per year large-cap
peer group current trade consensu earn feel in-lin multipl
appropri base alxn growth profil step back hold posit outlook
stori continu view soliris/ultomiri franchis hold strong competit
posit across multipl therapeut indic advanc multipl pipelin
effort think diversif stori start unfold come year remain
outperform rate
incom statement ms
good sold
 expens revenu
sg expens revenu
target deriv multipl ep discount back premium vs large-cap
consensu ep due orphan product portfolio pipelin
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori alexion employ acceler strategi gain approv market product regul may requir
addit data could alter requir approv necessit addit longer studi failur gain product
label lack certain featur could limit alexion abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti regeneron achillion competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur alexion exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
april
april
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
